A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
about
Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.Interrelations between psychiatric symptoms and drug-induced movement disorder.A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing processA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.Necrotising pyomyositis complicating intramuscular antipsychotic administration.Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review.Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesFactors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoateSwitching from brand-name to generic psychotropic medications: a literature review.Cognitive impairment associated with schizophrenia: a review of the humanistic burden.The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.Focusing on the adult attachment style in schizophrenia in community mental health centres: validation of the Psychosis Attachment Measure (PAM) in a German-speaking sample.Preparation, Characterization, and In Vivo Evaluation of Olanzapine Poly(D,L-lactide-co-glycolide) Microspheres.Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.Direct transition to long-acting risperidone--analysis of long-term efficacy.Long-acting risperidone in stable patients with schizoaffective disorder.Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers.Modified biopolymer-dextrin based crosslinked hydrogels: application in controlled drug deliverySymptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable
P2860
Q33464064-DB31A819-7678-4C74-B114-ED756823E083Q34573844-F1722C8F-69C7-4761-8431-D34732EAFB06Q34629537-676753CC-9496-4946-99E0-0A4818B2D321Q34660425-0FD625F2-E635-413D-B26F-9992C2DC497BQ35698817-334DBD23-68A4-4C8A-BB66-A4D5A09265DBQ36033253-28A097B2-DCF5-4EB0-8957-5589C2FCA33BQ36173759-8AB23BA1-77B7-465C-A8D7-F102E1052DF4Q36731884-AA1AE91E-1ED4-4324-8D9F-57BB9F3E166DQ37042180-87E53E02-9F4F-491A-BA37-00DFCE1DAC64Q37084123-AF398EC4-7494-4B71-9EEA-CE22749FA6BCQ37813190-46AB4890-A082-41AE-AA31-B698861BD216Q37986695-9B0AB493-E03C-4E4C-89AB-A8A80B796E86Q38089699-C7733FB1-F54E-482D-B769-528827A1D59EQ39289346-1A19C5D1-84D3-4207-B1DD-55008BD142E8Q39740155-BE207733-DB5A-428D-AD1F-400BA8216D51Q40335811-BD293FEF-6D9D-4426-9F27-8F1436120673Q42149681-F90BCAA8-BB7B-41F7-9121-138C7D4CE68DQ46495720-BCAFF299-72C6-4F17-9277-31F4B8FB8B2EQ46689236-4139F05A-BEA3-4202-9A44-1B45CFDCAB31Q46689239-57AED7A7-6E6D-4BFF-94BE-EC62C98ABE91Q48534531-D9511250-F539-4921-AA2B-D2D1104A9545Q57348080-4A759956-0F12-4AD4-86A6-C07F2530EAFFQ58896977-7ABA9E43-4DAB-4B87-AB41-BAC3EA9EB9DB
P2860
A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A review of compliance, depot ...... risperidone in schizophrenia.
@ast
A review of compliance, depot ...... risperidone in schizophrenia.
@en
type
label
A review of compliance, depot ...... risperidone in schizophrenia.
@ast
A review of compliance, depot ...... risperidone in schizophrenia.
@en
prefLabel
A review of compliance, depot ...... risperidone in schizophrenia.
@ast
A review of compliance, depot ...... risperidone in schizophrenia.
@en
P2093
P1476
A review of compliance, depot ...... risperidone in schizophrenia.
@en
P2093
Guy Chouinard
Howard C Margolese
Nadeem H Bhanji
P356
10.1016/S0924-977X(03)00109-3
P407
P577
2004-03-01T00:00:00Z